During the past 16 years I have focused on developing effective gene and cell therapy-based treatments for the treatment of cancer. In my early work, I designed an oncolytic adenovirus able to degrade the extracellular matrix of solid tumours. The results from this work lead to a well-cited publication in the field of virotherapy (Guedan, Molecular therapy, 2010) and to the filing of a patent that was used to create a new company, VCN Biosciences. Their first clinical candidate was based on the results generated during my PhD and is now being tested in two clinical trials for the treatment of cancer with encouraging results (NCT02045589, NCT03284268). I next moved to the University of Pennsylvania to develop new CAR-T cell therapies for the treatment of solid tumours, first as a Marie Curie Fellow, under the supervision of Dr. Carl June, and later as senior scientist, leading part of the June lab. During these years, I explored the effect of various costimulatory and transmembrane domains of CARs on the persistence and effector functions of various lymphocyte subsets (Guedan, JCI, 2020; Guedan, JCI Insight 2018, Guedan, Blood 2014). I also explored the combination of CAR-T cells with oncolytic adenoviruses expressing immune stimulating molecules, with the goal of enhancing the trafficking, activation and potency of CAR-T cells (Wing, Cancer Immunology Research 2018 and Watanabe, JCI Insight 2018). Based on these works, the combination of CAR-T cells and oncolytic viruses is currently being tested in a clinical trial in patients with pancreatic and ovarian cancers (NCT05057715). On May 2018, I was recruited by IDIBAPS to lead a CAR-T cell program for the treatment of solid tumours and hematologic malignancies. Since then, I have raised more than 3 million euros in competitive funding as principal investigator and published an original article as senior author (Schettini, ESMO Open 2021). I am the first author of six review articles on CAR-T cell therapies published in Q1 journals, including Annual Review in Immunology (Guedan, 2019). My leadership in the above-mentioned projects justified my signature as corresponding author in eleven of the articles and two book chapters published after my PhD studies. I am an inventor in six patents, all of them licensed to industry, which indicates my contribution in the conception of the inventions. Because of my achievements, I have been invited to present at more than 40 national and international conferences (including ESMO IO 2019, ESMO TAT 2021, EHA-EBMT CART 2020 and 2022, PEGS Europe 2020 and ESGCT 2021) and research centres and to teach at Universities. I have also been invited to write commentary articles (Guedan et al. CCR 2019), to review articles for journals (including JCI, Science Translational Medicine and Science Immunology), and to participate in the review process of grants, abstracts and posters at international conferences (i.e. ESGCT and ASGCT) and to chair sessions at international meetings (i.e. ESGCT, ICLE, EHA-EBMT CART). I am also a board member of the Spanish Society for Gene and Cell Therapy (SETGyC). I am currently a Ramon y Cajal Fellow (a highly prestigious 5-year tenure-track fellowship by the Spanish Government).  General Quality Indicators: Total publications: 30; Publications as  main author (first or last): 18; Publications as  corresponding: 13; Publications in  D1: 14 (46%); Publications in Q1: 23 (76%);  Highly cited paper (within 1% of the research field): 8 (6 as main author), Total citations: 2601 ( 656 citation in 2021). h-index: 21. Search performed on October 19th, 2022.